The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients

Allergy. 2023 Feb;78(2):571-574. doi: 10.1111/all.15540. Epub 2022 Oct 17.

¹ Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Department of Biomedical Engineering, the University of Mississippi, University, Mississippi, USA.
⁴ Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; T cell; atopic dermatitis; dupilumab.

Publication types